Sazali Suhairul, Badrin Salziyan, Norhayati Mohd Noor, Idris Nur Suhaila
Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia
BMJ Open. 2021 Jan 5;11(1):e039358. doi: 10.1136/bmjopen-2020-039358.
To determine the effects of coenzyme Q10 (CoQ10) for reduction in the severity, frequency of migraine attacks and duration of headache in adult patients with migraine.
Systematic review and meta-analysis.
Cochrane Central Register of Controlled Trials, CENTRAL, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Psychological Information Database (PsycINFO) from inception till December 2019.
All randomised control trials comparing CoQ10 with placebo or used as an adjunct treatment included in this meta-analysis. Cross-over designs and controlled clinical trials were excluded.
Heterogeneity at face value by comparing populations, settings, interventions and outcomes were measured and statistical heterogeneity was assessed by means of the I statistic. The treatment effect for dichotomous outcomes were using risk ratios and risk difference, and for continuous outcomes, mean differences (MDs) or standardised mean difference; both with 95% CIs were used. Subgroup analyses were carried out for dosage of CoQ10 and if CoQ10 combined with another supplementation. Sensitivity analysis was used to investigate the impact risk of bias for sequence generation and allocation concealment of included studies.
Six studies with a total of 371 participants were included in the meta-analysis. There is no statistically significant reduction in severity of migraine headache with CoQ10 supplementation. CoQ10 supplementation reduced the duration of headache attacks compared with the control group (MD: -0.19; 95% CI: -0.27 to -0.11; random effects; I statistic=0%; p<0.00001). CoQ10 usage reduced the frequency of migraine headache compared with the control group (MD: -1.52; 95% CI: -2.40 to -0.65; random effects; I statistic=0%; p<0.001).
CoQ10 appears to have beneficial effects in reducing duration and frequency of migraine attack.
CRD42019126127.
确定辅酶Q10（CoQ10）对减轻成年偏头痛患者偏头痛发作的严重程度、频率及头痛持续时间的效果。
系统评价与荟萃分析。
Cochrane对照试验中心注册库、CENTRAL、医学期刊数据库（MEDLINE）、荷兰医学文摘数据库（EMBASE）、护理学与健康相关文献累积索引数据库（CINAHL）以及心理学文摘数据库（PsycINFO），检索时间从建库至2019年12月。
本荟萃分析纳入所有比较CoQ10与安慰剂或作为辅助治疗的随机对照试验。交叉设计和对照临床试验被排除。
通过比较人群、研究背景、干预措施和结局来衡量表面异质性，并通过I统计量评估统计学异质性。二分类结局的治疗效果采用风险比和风险差，连续型结局采用平均差（MDs）或标准化平均差；均使用95%置信区间（CIs）。对CoQ10的剂量以及CoQ10是否与其他补充剂联合使用进行亚组分析。采用敏感性分析来研究纳入研究的序列生成和分配隐藏的偏倚风险影响。
六项研究共371名参与者被纳入荟萃分析。补充CoQ10后偏头痛头痛严重程度无统计学显著降低。与对照组相比，补充CoQ10可缩短头痛发作持续时间（MD：-0.19；95%CI：-0.27至-0.11；随机效应；I统计量=0%；p<0.00001）。与对照组相比，使用CoQ10可降低偏头痛头痛频率（MD：-1.52；95%CI：-2.40至-0.65；随机效应；I统计量=0%；p<0.001）。
CoQ10似乎对缩短偏头痛发作持续时间和频率有有益作用。
CRD42019126127。
